Figure 3. Expression of oligodendrocyte-specific cell type markers in F3.Olig2 cells and expression of motor neuron-specific cell type markers in F3.Olig2-Shh cells.
Image credit: Lee, et.al. 2014 under CC BY license

Funding Opportunities

To submit any new grant opportunities for this list, please email ALSgrants@prize4life.org. List the sponsor name, amount, due date, and contact information.

 


 

Current Funding Opportunities:


NEW! ALS Canada-Brain Canada Trainee Program
Sponsor: ALS Canada and Brain Canada
Description: It is crucial that promising young investigators are nurtured in the early stages of their careers, so they might strive to promote discovery and advancement. Attracting the brightest young minds to ALS research will contribute to a succession plan for the Canadian ALS research community and will nurture and support innovative ideas and compelling breakthroughs across the spectrum of brain-related disease. Both doctoral and postdoctoral trainee grants are available.
Deadline: Application due by May 25, 2018.



NEW! New Investigator Research Grant, Neuroscience (UK)
Sponsor: MRC
Description: The New Investigator Research Grant (NIRG) is aimed at researchers who are capable of becoming independent Principal Investigators and who are now ready to take the next step towards that goal. A NIRG is normally of three years duration and is not renewable.
Deadline: Application due by May 30, 2018.



NEW! MDA Venture Philanthropy Program
Sponsor: Muscular Dystrophy Association
Description: MDA’s MVP program is exclusively focused on funding the discovery and clinical application of treatments and cures for neuromuscular diseases. The diseases funded include ALS. MVP funds projects from proof-of-principle studies through phase 2 trials. The maximum award is  $1M USD for preclinical studies, $3M USD for early clinical studies and $500,000 USD for R&D.
Deadline: Letter of Intent due by June 1, 2018.



NEW! Research Grants
Sponsor: Muscular Dystrophy Association
Description: These grants are awarded to independent, established investigators to accelerate progress toward understanding and treating diseases that are neuromuscular in nature including ALS. The total award is $100,000 per year for one to three years. In a very limited number of cases, awards will exceed $100,000 per year, but pre-approval is required before letter of intent submission.
Deadline: Letter of Intent due by June 15, 2018.



NEW! ALSRP Therapeutic Development Award
Sponsor: US Department of Defense CDMRP
Description: The goal of the Amyotrophic Lateral Sclerosis Research Program is to fund innovative preclinical research to promote the development of new treatments that may contribute to a cure for ALS. The anticipated direct costs budgeted for the entire period of performance for an FY18 ALSRP Therapeutic Development Award will not exceed $1,000,000 USD, or $1,250,000 USD if applying under the Therapeutically Relevant Marker Option.
Deadline: Application due by June 22, 2018.



NEW! ALSRP Therapeutic Idea Award
Sponsor: US Department of Defense CDMRP
Description: The goal of the ALSRP is to fund innovative preclinical research to promote the development of new treatments that may contribute to a cure for ALS. The anticipated direct costs budgeted for the entire period of performance for an FY18 ALSRP Therapeutic Idea Award will not exceed $500,000 USD.
Deadline: Application due by June 22, 2018.



NEW! Scientific Innovations Award
Sponsor: Brain Research Foundation
Description: The Scientific Innovations Award supports innovative discovery science in both basic and clinical neuroscience. This funding mechanism is designed to support creative, cutting edge research in well-established research laboratories, under the direction of established investigators.
Deadline: Letter of Intent due by June 22, 2018.



NEW! Roger de Spoelberch Prize
Sponsor: Roger de Spoelberch Foundation
Description: Each year, the Foundation awards the Roger de Spoelberch Prize to a winner for a clinical and basic scientific research project in the area of neurodegenerative diseases and psychiatric disorders. The value of the prize currently amounts to 750,000 euros.
Deadline: Application due by June 29, 2018.



NEW! Nonclinical and Early-Phase Clinical Development for Biologics
Sponsor: NINDS, CREATE Bio Development Track
Description: This Funding Opportunity Announcement (FOA) supports the development of therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene therapies, cell therapies, and novel emerging therapies) for disorders identified under the NINDS mission. Investigational New Drug (IND)-enabling studies for a therapeutic candidate and the inclusion of an optional small delayed-onset first in human Phase I clinical trial will be funded. At the end of the funding period, a successful project should have at least an IND application submitted to the U.S. Food and Drug Administration (FDA).
Deadline: Application due by July 18, 2018.



NEW! Frick Foundation for ALS Research Award
Sponsor: Bruno and Ilse Frick Foundation for Research on ALS
Description: The aim of the Foundation is to encourage basic biomedical research related to understanding the cause of ALS. The funding is 100,000 CHF over 2 years.
Deadline: Application due by October 8, 2018.



Rapid Response: Ireland, Netherlands, UK (Includes FTD)
Sponsor: Weston Brain Institute
Description: The Rapid Response: Ireland, Netherlands, UK 2018 (Fluid Biomarkers) program was launched to provide seed funding, without requirement for preliminary data, to support high-risk, high-reward, translational research on novel biomarkers detected in patient-derived fluids. Up to £180,000 over up to 18 months per project will be awarded, with a total of £540,000 available for the full program. Principal Applicants must be at or above the level of Postdoctoral Researcher and at eligible institutions located in Ireland, the Netherlands, or the UK.
Deadline: Letter of Intent due by April 23, 2018.



Graduate Student Fellowship
Sponsor: AFM-Téléthon
Description: This International Call for Proposals, open to both French and foreign groups, aims to support research at the graduate student level which will increase our understanding of the neuromuscular system or encourgae the development of therapies for neuromuscular diseases and rare genetic diseases. Special attention will be given to: (1) projects on epigenetics in neuromuscular diseases and (2) projects on microbiota in neuromuscular diseases. Priority will be given to ALS research projects that could be also provide insight into the underlying mechanisms and/or treatment of SMA.
Deadline: Application due by April 24, 2018.



Teva CNS Target Identification Crowdsourcing Challenge
Sponsor: TEVA and the ALS Association
Description: This challenge calls on researchers from all over the world to submit proposals for novel drug targets implicated in CNS disorders, including amyotrophic lateral sclerosis (ALS). Proposed "solutions" will be considered for monetary awards and funded collaborative research projects with Teva - no strings attached. (Teva does not request ownership of intellectual property.) The top submissions will be considered for awards ranging from $10,000 to $30,000. Up to $40,000 in cash awards may be distributed.
Deadline: Proposals due by April 29, 2018.



Identify, Analyze and Evaluate Potential Risk Factors for ALS
Sponsor: CDC
Description: The purpose of this funding opportunity announcement (FOA) is to allow for investigator initiated research that will further the understanding of potential risk factors for ALS, while supporting the National ALS Registry's mission. Maximum award is $400,000 USD. A letter of intent is requested by April 2, 2018 for review planning purposes.
Deadline: Application due by April 30, 2018.



Graduate Studentships
Sponsor: MND Association
Description: The MND Association supports biomedical research on Amyotrophic Lateral Sclerosis and related conditions, in all relevant disciplines. The objectives of the MND Association research funding programme are to support research aimed at understanding the causes of MND, elucidating disease mechanisms and facilitating the translation of therapeutic strategies from the laboratory to the clinic. This grant supports the training of a graduate science student in order to achieve the qualification of PhD (or equivalent) in a subject of direct relevance to motor neurone disease. Applications will begin to be accepted March 9, 2018.
Deadline: Application due by May 4, 2018.



Non-Clinical Fellowships
Sponsor: MND Association
Description: We now invite post-doctoral scientists with relevant experience who are ready to lead a research project as Principal Investigator, to apply for an MND Association Non-clinical Fellowship Award. These awards will be open to scientists across a range of disciplines, excluding those with a medical qualification. The award may only be held at a university or other bona-fide research institute in the UK and Ireland – the host institute. Applications will begin to be accepted March 9, 2018.
Deadline: Application due by May 4, 2018.



Promotion of Translation-Oriented Collaborative Projects in the Field of Rare Diseases
Sponsor: German Federal Ministry of Education and Research (BMBF)
Description: This funding call intends to promote research networks that develop new insights into rare diseases through problem-solving and interdisciplinary cooperation. The chosen projects will be pursued in a cooperative and coordinated manner with the aim of sustainable and improved care for patients in the short- to medium-term. Research groups should conduct their research on a group of rare diseases or, in exceptional cases, on a single rare disease.
Deadline: Application due by May 8, 2018.



Harrington Scholar-Innovator Program (Physician-Scientists)
Sponsor: Harrington Discovery Institute
Description: The goal of the Harrington Scholar-Innovator Program is to advance physician-scientist-initiated projects aimed at clinical introduction of new medicines (drugs or biologics). The specific focus of eligible projects includes fundamental discovery (elucidation of novel targets and leads) or development of novel drugs or biologics or drug-device combinations. Awards are at least $100K USD, and are up to $700K USD.
Deadline: Application due by May 10, 2018.



ALS Canada Project Grant Program
Sponsor: ALS Canada
Description: This grant program funds the best projects including high risk/high reward with little preliminary data, continuation of ongoing high quality research and studies to improve the quality of life for people with ALS. Grants anticipated to be $125,000 CAD for use over 1 or 2 years.
Deadline: Application due by June 8, 2018.



ADDF NIH Scored Unfunded Grants (includes FTD)
Sponsor: Alzheimer's Drug Discovery Foundation
Description: This request for proposals supports NIA and NINDS grant proposals in NIH format that were scored but not funded, which fall within our mission and research priorities. This includes frontotemporal dementias.
Deadline: Applications are accepted on a rolling basis..



CLIN 2: Partnering Opportunity for Clinical Trial Stage Projects
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to create a highly competitive partnering opportunity for promising stem cell-based projects to accelerate the completion of a clinical trial for a stem cell treatment that addresses an unmet medical need.
Deadline: Last business day of each month.



CLIN 3: Partnering Opportunity for Supplemental Accelerating Activities
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to support new activities on active CIRM-funded development projects that will significantly accelerate development of the proposed treatment or increase the likelihood of success.
Deadline: Last business day of each month.



Catalyst Grant: New Genes for Rare Diseases
Sponsor: Rare Diseases Models and Mechanisms Network
Description: On behalf of the Clinical Advisory Committee of the Rare Diseases: Models and Mechanisms Network, the Co-Chairs would like to invite applications from clinicians and clinician scientists who have discovered novel genes in patients with rare diseases and wish to collaborate with a model organism investigator who is able to carry out functional analysis on an orthologous gene in a model system. A maximum of $25,000 CAD will be awarded. Applications may be submitted by any investigator associated with a Canadian Institution.
Deadline: Applications will be accepted on a rolling basis.



Clin1: Partnering Opportunity for Late Stage Preclinical Projects
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to create a highly competitive partnering opportunity for promising stem cell-based projects to accelerate the completion of preclinical activities necessary to attain an active IND or IDE with the FDA and to initiate start-up activities of the proposed clinical trial. CIRM expects projects under this program to advance rapidly into the clinic and to be accomplished within two years unless adequately justified.
Deadline: Last business day of each month.



Early Phase Clinical Trials, Canada (Includes FTD)
Sponsor: Weston Brain Institute
Description: The Early Phase Clinical Trials Canada program provides funding to support clinical trials and/or clinical trial sub-studies that could accelerate the development of therapeutics for neurodegenerative disease aging, including FTD. Eligible principal investigators must be at or above the level of Assistant Professor or equivalent, and be affiliated with a CRA-qualified institution located in Canada. A maximum of $1,500,000 per project over up to 4 years.
Deadline: Applications will be accepted on a rolling basis.



NIH TRND Program and NIH BrIDGs Program
Sponsor: NIH National Center for Advancing Translational Sciences (NCATS)
Description: NCATS is now accepting proposals on a rolling basis to collaborate with Bridging Interventional Development Gaps (BrIDGs) and Therapeutics for Rare and Neglected Diseases (TRND) program scientists. Click here to apply.
Deadline: Now accepting rolling applications.



NINDS Training and Career Development Awards
Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)
Description: NINDS offers a wide range of training and career development funding opportunities including pre-doctoral fellowships, post-doctoral fellowships, mentored career development awards, institutional programs, independent scientists awards, clinical research awards and more. All programs are open to researchers focusing on the study of ALS and related conditions.
Deadline: Varies, see individual program for details.



NeuroNEXT Infrastructure Resource Access
Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)
Description:

This funding opportunity announcement (FOA) encourages proposals for biomarker validation trials or exploratory clinical trials of drugs, biologics, surgical therapies or devices that may contribute to the justification for and provide the data required to design a future trial to confirm efficacy (i.e., a Phase III trial) in the treatment of neurologic disease. Proposals for drugs or biologics should provide compelling scientific evidence that the investigational agent proposed for study will reach/act upon the designated target or that its mechanism of action is such that it will be of benefit in ameliorating a specific aspect of the disease.

Diseases chosen for study should be based on the NINDS' strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm). Successful applicants will be given access to the NeuroNEXT infrastructure. The NeuroNEXT Clinical Coordinating Center (CCC) will work with the successful applicant to efficiently implement the proposed study. The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support. The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol.


Deadline: Now accepting rolling applications.



Transformational Research: Canada 2018
Sponsor: Weston Brain Institute
Description: This program funds transformative, novel, high-risk, high-reward translational research projects with excellent preliminary data aimed at accelerating the development of therapies for neurodegenerative diseases of aging including FTD. A maximum of $1,500,000 over up to 3 years per project. PIs must be at or above the level of Assistant Professor or equivalent, work in Canada at least 30% of the time, and be affiliated with a CRA-qualified institution.
Deadline: February 15, 2018 (extended).



Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail